MDT

98.74

-1.06%↓

A

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

A

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

A

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

A

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

MDT

98.74

-1.06%↓

A

145.66

-1.47%↓

VEEV

241.02

+0.99%↑

HQY

98.46

+0.84%↑

PHR.US

16.88

-3.21%↓

Search

Simulations Plus Inc

Slēgts

SektorsVeselības aprūpe

17.94 -5.13

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

17.8

Max

18.77

Galvenie mērījumi

By Trading Economics

Ienākumi

-681K

Pārdošana

17M

P/E

Sektora vidējais

48.528

87.826

EPS

-0.034

Dividenžu ienesīgums

0.48

Peļņas marža

-3.9

Darbinieki

212

EBITDA

-79M

-74M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+15.85% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.48%

2.26%

Nākamie ieņēmumi

2026. g. 8. janv.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

19M

387M

Iepriekšējā atvēršanas cena

23.07

Iepriekšējā slēgšanas cena

17.94

Ziņu noskaņojums

By Acuity

50%

50%

166 / 372 Rangs Healthcare

Simulations Plus Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 7. janv. 23:11 UTC

Peļņas

Samsung Electronics Expects Record Fourth-Quarter Profit Beat

2026. g. 7. janv. 22:55 UTC

Galvenie tirgus virzītāji

Defense Stocks Rebound After Trump Says He Wants $1.5 Trillion Military Budget in 2027

2026. g. 7. janv. 21:39 UTC

Galvenie tirgus virzītāji

Raytheon Down Following Trump Post Criticizing Company

2026. g. 7. janv. 20:13 UTC

Galvenie tirgus virzītāji

AbbVie, Revolution Medicines Stocks Gain on Report of Possible Acquisition

2026. g. 7. janv. 20:03 UTC

Galvenie tirgus virzītāji

Defense Contractor Shares Fall on Trump's Push to Ban Industry Dividends, Buybacks, Limit Executive Pay

2026. g. 7. janv. 23:46 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 7. janv. 23:46 UTC

Tirgus saruna

Nikkei May Decline as China-Japan Tensions Linger -- Market Talk

2026. g. 7. janv. 23:42 UTC

Iegādes, apvienošanās, pārņemšana

Warner Discovery Rejects Paramount's Amended Hostile Bid -- 5th Update

2026. g. 7. janv. 23:34 UTC

Tirgus saruna

Gold Edges Higher Amid Lingering Geopolitical Risks -- Market Talk

2026. g. 7. janv. 23:29 UTC

Iegādes, apvienošanās, pārņemšana

Constellation Closes Deal for Calpine, Creating Biggest Electricity Generator -- Barrons.com

2026. g. 7. janv. 22:48 UTC

Tirgus saruna

Infratil's Discount to Net Asset Value Too Good to Ignore -- Market Talk

2026. g. 7. janv. 22:46 UTC

Peļņas

Samsung Electronics Estimates 2025 Rev KRW332.770T Vs KRW300.870T >005930.SE

2026. g. 7. janv. 22:45 UTC

Peļņas

Samsung Electronics Estimates 2025 Oper Pft KRW43.530T Vs KRW32.730T >005930.SE

2026. g. 7. janv. 22:43 UTC

Iegādes, apvienošanās, pārņemšana

Revolution Medicines Draws Takeover Interest -- 2nd Update

2026. g. 7. janv. 22:42 UTC

Peļņas

Samsung Electronics 4Q Oper Pft Estimate Beat FactSet-Compiled Consensus Forecast

2026. g. 7. janv. 22:41 UTC

Peļņas

Samsung Electronics Sees 4Q Oper Pft KRW20.000T Vs KRW6.490T >005930.SE

2026. g. 7. janv. 22:41 UTC

Peļņas

Samsung Electronics Sees 4Q Rev KRW93.000T Vs KRW75.790T >005930.SE

2026. g. 7. janv. 22:40 UTC

Galvenie tirgus virzītāji

Defense Stocks Rebound After Trump Says He Wants $1.5T Military Budget in 2027

2026. g. 7. janv. 22:31 UTC

Tirgus saruna

Macro Tailwinds Strengthen for Chalice Mining -- Market Talk

2026. g. 7. janv. 22:22 UTC

Tirgus saruna

Northern Star's Run of Disruptions Increasingly a Concern -- Market Talk

2026. g. 7. janv. 22:01 UTC

Tirgus saruna

Valuations of New Zealand Property Stocks Supportive -- Market Talk

2026. g. 7. janv. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 7. janv. 21:46 UTC

Tirgus saruna

Northern Star's Revised Guidance Looks Achievable -- Market Talk

2026. g. 7. janv. 21:22 UTC

Iegādes, apvienošanās, pārņemšana

Eli Lilly to Buy Ventyx Biosciences for $14 a Share >LLY VTYX

2026. g. 7. janv. 21:18 UTC

Iegādes, apvienošanās, pārņemšana

Lilly To Acquire Ventyx Biosciences To Advance Oral Therapies Targeting Inflammatory-mediated Diseases >LLY VTYX

2026. g. 7. janv. 21:05 UTC

Iegādes, apvienošanās, pārņemšana

Warner Discovery Rejects Paramount's Amended Hostile Bid -- 4th Update

2026. g. 7. janv. 20:29 UTC

Iegādes, apvienošanās, pārņemšana

AbbVie Near Deal for Revolution Medicines -- Update

2026. g. 7. janv. 20:27 UTC

Tirgus saruna

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

2026. g. 7. janv. 19:58 UTC

Tirgus saruna

Oil Falls As U.S. to Receive Sanctioned Venezuelan Crude -- Market Talk

2026. g. 7. janv. 19:48 UTC

Galvenie tirgus virzītāji

Defense Contractor Shares Fall on Trump's Push to Ban Industry Dividends, Buybacks, Limit Exec Pay

Salīdzinājums

Cenas izmaiņa

Simulations Plus Inc Prognoze

Cenas mērķis

By TipRanks

15.85% augšup

Prognoze 12 mēnešiem

Vidējais 22 USD  15.85%

Augstākais 25 USD

Zemākais 19 USD

Pamatojoties uz 5 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

5 ratings

2

Pirkt

3

Turēt

0

Pārdot

Noskaņojums

By Acuity

166 / 372 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat